PDCD1 and neoplasm: However, considering the survival rate with systemic therapy and the fact that tumor cell death induced by HN-PIT activates local and peripheral T-cell responses, HN-PIT administration followed by PD-1 inhibitors after treatment failure may be the best combination at this point.